Blueprint Medicines Corporation (BPMC)
- Previous Close
92.26 - Open
89.54 - Bid 88.66 x 400
- Ask 89.62 x 200
- Day's Range
88.46 - 90.29 - 52 Week Range
43.89 - 101.00 - Volume
25,221 - Avg. Volume
798,735 - Market Cap (intraday)
5.474B - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
-- - EPS (TTM)
-8.37 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
97.38
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
www.blueprintmedicines.comRecent News: BPMC
Performance Overview: BPMC
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BPMC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BPMC
Valuation Measures
Market Cap
5.65B
Enterprise Value
5.27B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
22.40
Price/Book (mrq)
43.25
Enterprise Value/Revenue
21.14
Enterprise Value/EBITDA
-11.21
Financial Highlights
Profitability and Income Statement
Profit Margin
-203.30%
Return on Assets (ttm)
-25.34%
Return on Equity (ttm)
-157.13%
Revenue (ttm)
249.38M
Net Income Avi to Common (ttm)
-506.98M
Diluted EPS (ttm)
-8.37
Balance Sheet and Cash Flow
Total Cash (mrq)
710.64M
Total Debt/Equity (mrq)
592.70%
Levered Free Cash Flow (ttm)
-239.41M